Skip to content Norwegian Medical Products Agency Norwegian Medical Products Agency

Consultations on inclusion in the substitution list

Published:

Changes

  • : Lenket til NO-side der høringene er tilgjengelig.

The inclusion of medicines in the substitution list must, in certain cases, be sent for consultation. Such consultations are distributed to relevant stakeholders, typically with a consultation period of three weeks.

Page contents

    Criteria for when inclusion in the substitution list is sent for consultation: 

    • The medicines have not been assessed with a bioequivalence study (with some exceptions). 
    • The medicines have been granted marketing authorization based on a bibliographic application (Medicinal Products Regulation § 3-12 – Article 10a – well-established use). 
    • The medicines have been granted marketing authorization based on a biosimilar application (Article 10(4)). 
    • The medicines are for local use (eye, ear, skin, and mucous membranes) where bioequivalence is not relevant. 
    • NOMA seeks input on the evaluation of medical equivalence and considerations regarding medicine substitution in pharmacies. 

    Consultations

    Please see the Norwegian version of this page to see updates on consultations.